Monitoring incorporation, transformation and subcellular distribution of N-l-leucyl-doxorubicin in uterine sarcoma cells using capillary electrophoretic techniques

Cancer Letters

Volumn 262, Issue 1, 2008, Pages 123-132

  Wang, Yaohua ^a   Arriaga, Edgar A ^a  

^a University of Minnesota   (United States)

Author keywords

Cytotoxicity; Doxorubicin; MEKC LIF; MES SA; MES SA Dx5; N l leucyl doxorubicin; Prodrug; Subcellular

Indexed keywords

DOXORUBICIN; DRUG DERIVATIVE; LEURUBICIN; N-LEUCYLDOXORUBICIN; PRODRUG;

ARTICLE; CAPILLARY ELECTROPHORESIS; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; METHODOLOGY; SARCOMA; TISSUE DISTRIBUTION; TUMOR CELL LINE; UTERUS CANCER;

CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, CAPILLARY; FEMALE; HUMANS; PRODRUGS; SARCOMA; TISSUE DISTRIBUTION; UTERINE NEOPLASMS;

EID: 77951096980     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.11.034     Document Type: Article

References (33)

1. Blum R.H., Carter S.K. Adriamycin. A new anticancer drug with significant clinical activity. Ann. Intern. Med. 1974, 80:249-259.
2. Young R.C., Ozols R.F., Myers C.E. The anthracycline antineoplastic drugs. New Engl. J. Med. 1981, 305:139-153.
3. Trouet A., Deprez-De Campeenre D., Baurain R., Masquelier M. N-l-leucyl derivatives of daunorubicin and doxorubicin as new prodrugs of anthracyclines. Anthracyclines: current status and future developments 1983, 179-181. Masson Pub. USA, New York. G. Mathé, R. Maral, R. De Jager (Eds.).
4. Masquelier M., Baurain R., Trouet A. Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion. J. Med. Chem. 1980, 23:1166-1170.
5. Zbinden G., DeCampeenere D., Baurain R. Preclinical assessment of the cardiotoxic potential of anthracycline antibiotics: N-l-leucyl-doxorubicin. Arch. Toxicol. Suppl. 1991, 14:107-117.
6. Breistol K., Hendriks H.R., Berger D.P., Langdon S.P., Fiebig H.H., Fodstad O. The antitumour activity of the prodrug N-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts. Eur. J. Cancer 1998, 34:1602-1606.
7. Breistol K., Hendriks H.R., Fodstad O. Superior therapeutic efficacy of N-l-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug. Eur. J. Cancer 1999, 35:1143-1149.
8. de Jong J., Geijssen G.J., Munniksma C.N., Vermorken J.B., van der Vijgh W.J.F. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyl-doxorubicin and its metabolites in a phase I clinical trial. J. Clin. Oncol. 1992, 10:1897-1906.
9. de Jong J., Vermorken J.B., Van der Vijgh W.J.F. Analysis and pharmacokinetics of a new prodrug N-l-leucyldoxorubicin and its metabolites in plasma using HPLC with fluorescence detection. J. Pharm. Biomed. Anal. 1992, 10:309-314.
10. de Jong J., Klein I., Bast A., van der Vijgh W.J.F. Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. Cancer Chemother. Pharmacol. 1992, 31:156-160.
11. Wilstermann A.M., Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr. Top. Med. Chem. 2003, 3:321-338.
12. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
13. Reinhoud N.J., Tjaden U.R., Irth H., van der Greef J. Bioanalysis of some anthracyclines in human plasma by capillary electrophoresis with laser-induced fluorescence detection. J. Chromatogr. 1992, 574:327-334.
14. Simeon N., Chatelut E., Canal P., Nertz M., Couderc F. Anthracycline analysis by capillary electrophoresis. Application to the analysis of daunorubicine in Kaposi sarcoma tumor. J. Chromatogr. A. 1999, 853:449-454.
15. Anderson A.B., Ciriacks C.M., Fuller K.M., Arriaga E.A. Distribution of zeptomole-abundant doxorubicin metabolites in subcellular fractions by capillary electrophoresis with laser-induced fluorescence detection. Anal. Chem. 2003, 75:8-15.
16. Anderson A.B., Gergen J., Arriaga E.A. Detection of doxorubicin and metabolites in cell extracts and in single cells by capillary electrophoresis with laser-induced fluorescence detection. J. Chromatogr. B. 2002, 769:97-106.
17. Gosland M.P., Lum B.L., Sikic B.I. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res. 1989, 49:6901-6905.
18. Chen G., Duran G.E., Steger K.A., Lacayo N.J., Jaffrezou J.P., Dumontet C., Sikic B.I. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J. Biol. Chem. 1997, 272:5974-5982.
19. Lau D.H., Duran G.E., Lewis A.D., Sikic B.I. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br. J. Cancer 1994, 70:79-84.
20. Battisti R.F., Zhong Y., Fang L., Gibbs S., Shen J., Nadas J., Zhang G., Sun D. Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance. Mol. Pharm. 2007, 4:140-153.
21. Stelakatos G.C., Theodoropoulos D.M., Zervas L. On the trityl method for peptide synthesis. J. Am. Chem. Soc. 1959, 81:2884-2887.
22. Anderson G.W., Zimmerman J.E., Callahan F.M. The use of easter of N-hydroxysuccinimide in peptide synthesis. J. Am. Chem. Soc. 1964, 86:1839-1842.
23. Sobottka S.B., Berger M.R. Assessment of antineoplastic agents by MTT assay - partial underestimation of antiproliferative properties. Cancer Chemother. Pharmacol. 1992, 30:385-393.
24. Graham J.M., Rickwood D. Subcellular fractionation: a practical approach 1997, IRL Press at Oxford University Press, Oxford.
25. Duffy C.F., Gafoor S., Richards D.P., Admadzadeh H., O'Kennedy R., Arriaga E.A. Determination of properties of individual liposomes by capillary electrophoresis with postcolumn laser-induced fluorescence detection. Anal. Chem. 2001, 73:1855-1861.
26. Eder A.R., Chen J.S., Arriaga E.A. Separation of doxorubicin and doxorubicinol by cyclodextrin-modified micellar electrokinetic capillary chromatography. Electrophoresis 2006, 27:3263-3270.
27. Dalmark M., Storm H.H. A Fickian diffusion transport process with features of transport catalysis. Doxorubicin transport in human red blood cells. J. Gen. Physiol. 1981, 78:349-364.
28. Harker W.G., Sikic B.I. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res. 1985, 45:4091-4096.
29. Eder A.R., Arriaga E.A. Micellar electrokinetic capillary chromatography reveals differences in intracellular metabolism between liposomal and free doxorubicin treatment of human leukemia cells. J. Chromatogr. B. 2005, 829:115-122.
30. Li X.F., Ren H., Le X., Qi M., Ireland I.D., Dovichi N.J. Migration time correction for the analysis of derivatized amino acids and oligosaccharides by micellar capillary electrochromatography. J. Chromatogr A 2000, 869:375-384.
31. Bennis S., Garcia C., Robert J. Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines. Biochem. Pharmacol. 1993, 45:1929-1931.
32. Schindler M., Grabski S., Hoff E., Simon S.M. Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry 1996, 35:2811-2817.
33. Zijlstra J.G., de Vries E.G., Mulder N.H. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1987, 47:1780-1784.